Harnessing the Power of the Innate Immune System

Learn More

Our Science

Pulmotect’s lead product, PUL-042, is a clinical stage inhaled therapeutic that stimulates the innate immune system in the lungs to provide immediate and effective protection in animal models against all major classes of pathogens.

Learn More

Our Approach

Phase I/2a clinical trials demonstrated that PUL-042 was well tolerated in healthy individuals and subjects with COPD. Two phase 2 studies have completed enrollment for the prevention and treatment of COVID-19 with funding from the Department of Defense, with data read outs in Q3/Q4 2021. Phase 2 studies are being planned to assess the effectiveness of PUL-042 in preventing respiratory complications and improving outcomes in immunocompromised cancer patients.

Learn More